Company news
Thalia Therapeutics Plc (LSE:THAT) news
Every Thalia Therapeutics Plc press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Grant of Director Share Options
July 23, 2026
Result of AGM and Completion of Acquisition
July 17, 2026
Acquisition and £2.75 million Fundraise
June 24, 2026
New article: RNA medicine enters its second act
June 9, 2026
CEO Interview
June 2, 2026
CEO Interview: Thalia’s RNA Therapeutics Strategy
May 13, 2026
Change of Registered Address
April 20, 2026
Result of General Meeting and Change of Name
March 17, 2026
Notice of GM and Proposed Change of Name
February 27, 2026
CEO Appointment & Name Change Thalia Therapeutics
February 24, 2026
Business and Operational Update
December 17, 2025
Interim Results
September 25, 2025
Partnership with University of Strathclyde’s CMAC
September 23, 2025
N4 Pharma’s Nuvec® Targets Lung Cancer Cells
September 22, 2025
Notice of Results, Analyst & Investor Presentation
September 19, 2025
Investor Event and Presentation
September 11, 2025
Article on Nuvec®’s Potential in RNA Therapeutics
July 30, 2025
Investor Webinar
July 14, 2025
Directorate Change
July 8, 2025
Result of AGM
June 30, 2025
Insight Event for Retail Investors
June 25, 2025
Final Results, Annual Report and Notice of AGM
June 6, 2025
Establishment of New Senior Leadership Team
May 27, 2025
TR-1: Notification of major holdings
May 23, 2025
Holding(s) in Company
May 21, 2025
N4 101 In Vivo Study Results
May 12, 2025
TR-1: Standard form notification of major holdings
April 23, 2025
Result of General Meeting
April 22, 2025
Posting of Circular and Notice of General Meeting
April 4, 2025
Placing and Subscription to raise £1,750,000
April 1, 2025
N4 Pharma Non-Executive Director Q&A
January 16, 2025
Directorate Changes
January 8, 2025
N4 101 In Vitro Results
December 12, 2024
New Patent Filing
December 4, 2024
Grant of Options
November 28, 2024
N4 Pharma CEO Q&A Now LIVE
November 1, 2024
New Corporate Presentation
October 24, 2024
SRI Research Update
September 17, 2024
Director Appointment
September 9, 2024
Change of Auditor
August 23, 2024
Nanogenics Update
July 3, 2024
Total Voting Rights
June 28, 2024
Placing and Subscription to raise £630,000
June 7, 2024
Posting of Annual Report & Notice of AGM
April 29, 2024
N4 Pharma Webinar on SRI Collaboration
April 26, 2024
Collaboration Agreement with SRI International Inc
April 25, 2024
Final Results
April 23, 2024
Oral Delivery Update
April 18, 2024
in-vitro siRNA update
February 15, 2024
Patent Grant
January 19, 2024